It not a case of ethics it is a case of 1st publisher acceptance. $ONCS has put a ton of work and $mil into their Melanoma Clinical trials. The Window of opportunity was only a few weeks wide between ASCO and ASGCT . To only submit to one when the deadlines were only a few weeks apart was to drastically limit the possibilities of prestigious Peer Review publication.
The other question to ask is why wouldn't they have sent their premier Melanoma P1/2 abstract to ASCO.
As I said waiting for $ONCS to clarify the situation.
Trading.jeff, totally agree. If ONCS submitted the same abstract to both meetings, it looks really bad if they have to pull one of them. You also point it out that it is unethical.
News 
Market Data 
Discover 
AI
